Biomica Appoints Professor Gal Markel to Company’s Scientific Advisory Board
This addition to Biomica’s scientific expertise will support the company’s upcoming steps in its immuno-oncology clinical development program
Rehovot, Israel – July 28, 2022 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd.
Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug
REHOVOT, Israel, July 26, 2022 – Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), today announced that the first patient was dosed in its Phase I clinical trial that is designed primarily to evaluate the safety and tolerability of Biomica’s microbiome-based immuno-oncology drug candidate,
Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug
Proof of Concept (POC) in-human trial to take place at Rambam Health Care Campus in Israel throughout 2022
REHOVOT, Israel, July 11, 2022. Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd.
Biomica to Present at the Microbiome Connect Europe 2022
Rehovot, Israel – July 5, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN, TASE: EVGN), today announced it will be presenting at Microbiome Connect Europe taking place between July 6-7, 2022, in Amsterdam,
Microbiome Connect Europe 2022
Microbiome Movement – Drug Development Summit
Biomica to Present at the 7th Microbiome Movement Drug Development Summit
Dr. Elran Haber to participate in the Industry Leaders opening panel at this premier Microbiome conference
Rehovot, Israel – June 15, 2022 – Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics,